hydroxychloroquine has been researched along with Weight Loss in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC)." | 9.51 | Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. ( Amaravadi, RK; Brown, TJ; DiCicco, L; Garcia-Marcano, L; Karasic, TB; Massa, RC; Mitchell, TC; O'Dwyer, PJ; O'Hara, MH; Reiss, KA; Schneider, C; Teitelbaum, UR, 2022) |
| "The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC)." | 5.51 | Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. ( Amaravadi, RK; Brown, TJ; DiCicco, L; Garcia-Marcano, L; Karasic, TB; Massa, RC; Mitchell, TC; O'Dwyer, PJ; O'Hara, MH; Reiss, KA; Schneider, C; Teitelbaum, UR, 2022) |
| "A 59-year-old man with a history of ischemic-labeled heart disease revealed by conduction disorders and cutaneous lupus treated initially with hydroxychloroquine followed by chloroquine consulted for asthenia and weight loss." | 3.96 | [A rare cause of impaired general condition: Muscular and cardiac toxicity of antimalarials]. ( Costedoat-Chalumeau, N; Dion, J; Lenfant, T; Maisonobe, T, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karasic, TB | 1 |
| Brown, TJ | 1 |
| Schneider, C | 1 |
| Teitelbaum, UR | 1 |
| Reiss, KA | 1 |
| Mitchell, TC | 1 |
| Massa, RC | 1 |
| O'Hara, MH | 1 |
| DiCicco, L | 1 |
| Garcia-Marcano, L | 1 |
| Amaravadi, RK | 1 |
| O'Dwyer, PJ | 1 |
| Lenfant, T | 1 |
| Dion, J | 1 |
| Maisonobe, T | 1 |
| Costedoat-Chalumeau, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer[NCT03215264] | Phase 1 | 20 participants (Actual) | Interventional | 2017-10-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants were evaluable for toxicity if they have taken one dose of HCQ and one dose of entinostat. To be considered for evaluability in a Phase I cohort in the absence of dose-limiting toxicity, patients should have completed > 85% of HCQ doses, and at least 3 of 4 entinostat doses. The MTD will be defined as a) the dose producing DLT in 1 out of 6 patients, or b) the dose level below the dose which produced DLT in ≥ 2 out of 3 patients, or in ≥ 2 out of 6 patients. DLTs will be defined by toxicity occurring during the first 4 weeks of this study. (NCT03215264)
Timeframe: 18 months
| Intervention | mg (Number) | |
|---|---|---|
| Hydroxychloroquine Daily | Entinostat weekly | |
| All Participants | 1200 | 5 |
1 trial available for hydroxychloroquine and Weight Loss
| Article | Year |
|---|---|
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colorectal Neop | 2022 |
1 other study available for hydroxychloroquine and Weight Loss
| Article | Year |
|---|---|
[A rare cause of impaired general condition: Muscular and cardiac toxicity of antimalarials].
Topics: Antimalarials; Asthenia; Biopsy; Cardiotoxicity; Diagnosis, Differential; Humans; Hydroxychloroquine | 2020 |